Patent ID: 11958893
Assignee: CUE BIOPHARMA, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 5:
6. A method of treating according to claim 1,
wherein the Ig Fc polypeptide comprises an amino acid sequence having at least about 95% amino acid sequence identity to SEQ ID NO:21, and wherein the Ig Fc polypeptide comprises an L 14A substitution and an LISA substitution based on the amino acid numbering depicted in SEQ ID NO:44;
wherein the β2M polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to amino acids 21-119 of the amino acid sequence set forth in SEQ ID NO:95, and wherein the 132M polypeptide comprises a Cys at amino acid 12,
wherein the MHC class I heavy chain polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:50, wherein the MHC class I heavy chain polypeptide comprises a Cys at amino acid 236,
wherein each heterodimer of the protein comprises a disulfide bond between the first and second polypeptides, wherein the disulfide bond is between the Cys residue at amino acid 12 of the (32M polypeptide and the Cys residue at amino acid 236 of the MHC class I heavy chain polypeptide, and
wherein the second polypeptide comprises a peptide linker between one or more of:
a) a first copy of the variant IL-2 polypeptide and a second copy of the variant IL-2 polypeptide;
b) one of the two copies of the variant IL-2 polypeptide and the MHC class I heavy chain polypeptide; and
c) the MHC class I heavy chain polypeptide and the Ig Fc polypeptide.